Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 378,600 shares, a decline of 41.3% from the June 15th total of 644,700 shares. Based on an average trading volume of 967,600 shares, the short-interest ratio is presently 0.4 days. Approximately 2.5% of the company's shares are sold short.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group cut their price target on shares of Finch Therapeutics Group from $29.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, April 4th.
Get Finch Therapeutics Group alerts:Institutional Trading of Finch Therapeutics Group
A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Finch Therapeutics Group by 19.4% during the 1st quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock valued at $226,000 after buying an additional 7,314 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Finch Therapeutics Group by 2.3% during the 1st quarter. BlackRock Inc. now owns 404,931 shares of the company's stock valued at $2,038,000 after buying an additional 9,149 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Finch Therapeutics Group by 53.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock valued at $189,000 after buying an additional 13,128 shares in the last quarter. Lake Street Advisors Group LLC boosted its holdings in shares of Finch Therapeutics Group by 16.2% during the 4th quarter. Lake Street Advisors Group LLC now owns 739,136 shares of the company's stock valued at $7,369,000 after buying an additional 102,941 shares in the last quarter. Finally, Light Street Capital Management LLC boosted its holdings in shares of Finch Therapeutics Group by 1.8% during the 4th quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock valued at $8,093,000 after buying an additional 14,400 shares in the last quarter. Institutional investors own 22.68% of the company's stock.
Finch Therapeutics Group Stock Performance
NASDAQ:FNCH traded down $0.13 during trading hours on Friday, hitting $2.28. The company had a trading volume of 45,466 shares, compared to its average volume of 119,946. The stock has a 50-day moving average price of $2.47 and a 200 day moving average price of $5.14. Finch Therapeutics Group has a 52 week low of $1.71 and a 52 week high of $17.39.Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $0.35 million during the quarter. Finch Therapeutics Group had a negative net margin of 448.35% and a negative return on equity of 33.13%. As a group, research analysts predict that Finch Therapeutics Group will post -1.98 EPS for the current year.
Finch Therapeutics Group Company Profile
(Get Rating)
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
Further Reading
- Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
- MarketBeat: Week in Review 7/11 – 7/15
- Should You Have These Two Banks In Your Portfolio?
- Is Coupang's Stock On The Verge Of A Turnaround?
- Why Shopify Stock Split...And is as Shoppable as Ever
- Verint Systems Stock is a Customer Engagement Play
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.